Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial.

ABSTRACT:

Background

Glenzocimab is a novel antithrombotic agent which targets platelet glycoprotein VI (GPVI) and does not induce haemorrhage. SARS-CoV-2 triggers a prothrombotic state and lung injury whose mechanisms include coagulopathy, endothelial dysfunction, and inflammation with dysregulated platelets.

Methods and patients

GARDEN was a randomised double-blind, exploratory phase II study of glenzocimab in SARS-CoV-2 respiratory failure (NCT04659109). PCR+ adults in Brazil and France (7 centres) were randomized to standard-of-care (SOC) plus glenzocimab (1000 mg/dayx3 days) or placebo, followed for 40 days. Primary efficacy endpoint was clinical progression at Day 4. All analyses concerned the intention-to-treat population.

Results

Between December 2020 and August 2021, 6

SUBMITTER: Pottecher J 

PROVIDER: S-EPMC11182546 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature